Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms
Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS...
Gespeichert in:
Veröffentlicht in: | Future oncology (London, England) England), 2016-08, Vol.12 (16), p.1877 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Conclusion:90Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes. |
---|---|
ISSN: | 1479-6694 1744-8301 |
DOI: | 10.2217/fon-2016-0031 |